Clinical Study
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
Table 1
Patient characteristics.
| Age | Gender | NY-ESO-1 immuno-histochemistry | HLA-A2 | HLA-DP4 | ECOG performance status | Time to progression (months) | Overall survival (months) |
| 43 | F | 3+ | + | + | 1 | 1.9 | 3.8 | 26 | F | 4+ | + | + | 1 | 0.9 | 19.7 | 56 | M | 3+ | + | + | 0 | 1.9 | 13.7 | 32 | F | 3+ | − | + | 1 | 2.1 | 3.2 | 57 | F | 3+ | − | − | 2 | 0.5 | 0.8 | 23 | M | 2+ | + | + | 1 | 1.8 | 13.7 |
|
|